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mol considering pain relief, pain intensity difference, patient’s
global treatment satisfaction and between intravenous paraceta-
mol and metamizole on pain scores and pain scores on coughing.
Intravenous paracetamol had safety proﬁle similar to placebo.
Adults treated with intravenous paracetamol had 9 times lower
risk of adverse events (RR = 0.11; 95%CI: 0.05–0.24) and 30
times lower risk of infusion site reactions (RR = 0.03; 95%CI:
0.01–0.16), comparing with propacetamol. CONCLUSIONS:
Intravenous paracetamol is an effective drug in postoperative pain
management in children and adults as superior to oral paraceta-
mol and placebo. Its efﬁcacy is comparable to propacetamol and
metamizole, with better safety proﬁle.
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META-ANALYSIS OF DULOXETINE VS. PREGABALIN AND
GABAPENTIN IN THE TREATMENT OF PERIPHERAL DIABETIC
NEUROPATHIC PAIN
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OBJECTIVE: To compare the efﬁcacy and tolerability of dulox-
etine (DLX) with pregabalin (PGB) and gabapentin (GBP) for the
treatment of diabetic peripheral neuropathic pain (DPNP).
METHODS: We searched PubMed, Ovid, CENTRAL databases
and regulatory websites for randomized, double-blind, placebo-
controlled, parallel group or crossover clinical trials (RCTs)
assessing DLX, PGB and GBP in DPNP. Study arms using
approved dosages with assessments after 5–13 weeks were eligi-
ble. Efﬁcacy criteria were: reduction in 24-hour pain severity
(24hPS) for all three drugs, and response rate (>50% pain reduc-
tion) and Patient’s Global Impression of Improvement/Change
(PGI-I/C) for DLX and PGB only. Tolerability criteria were: 
discontinuation, diarrhoea, dizziness, headache, nausea and
somnolence. Pooled ﬁxed- and random-effects analyses were
conducted on endpoints reported in at least two studies of each
drug. Each drug was compared with placebo. DLX was com-
pared indirectly with PGB and GBP by meta-regression.
RESULTS: Three studies of DLX, 6 of PGB and 2 of GBP were
eligible. Between-study heterogeneity was insigniﬁcant. In
random-effects and ﬁxed-effects analyses, all drugs were supe-
rior to placebo for all efﬁcacy parameters, with some tolerabil-
ity trade-offs. Indirect comparison of DLX with PGB found no
differences in 24hPS, but signiﬁcant differences in PGI-I/C,
favouring PGB, and dizziness, favouring DLX were apparent.
Comparing DLX and GBP, there were no statistically signiﬁcant
differences. CONCLUSIONS: From the few studies available for
indirect comparison, DLX shows comparable efﬁcacy and toler-
ability to GBP and PGB in DPNP. Duloxetine provides an impor-
tant treatment option for this disabling condition.
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OBJECTIVES: Comparison of safety of intravenous metamizole,
ketoprofen and paracetamol based on data from WHO Pro-
gramme for International Drug Monitoring. METHODS: The
data from countries participating in the World Health Organi-
zation Programme for International Drug Monitoring are col-
lected and maintained, on behalf of the WHO, by the Uppsala
Monitoring Centre, in the Vigibase. An analysis of data on
adverse events (AE) of intravenous formulations of metamizole,
ketoprofen and paracetamol, reported to Vigibase, from Euro-
pean countries since 1968 up to 29th January 2006 (ref: ER
132/2005), was performed. RESULTS: One thousand three
hundred seventy one individual case reports of metamizole
adverse events were registered in the Vigibase, compared to 367
and 69 for ketoprofen and paracetamol, respectively. Serious AE
were reported in 29 metamizole cases, 47—ketoprofen and none
for paracetamol. There were 15 death cases registered for
metamizole, 1 for ketoprofen and paracetamol. Hematologic dis-
orders were reported in 187 metamizole cases, i.e. 6 and 31 times
more common then for ketoprofen and paracetamol therapy,
respectively. Most frequent AE reports for metamizole were: ana-
phylactic shock (79 cases versus 6 and 3 with ketoprofen and
paracetamol, respectively), agranulocytosis (77 vs 3 vs 1), rash
erythematous (63 vs 26 vs 3), hypotension (54 vs 6 vs 3), pruri-
tus (53 vs 10 vs 1), rash (51 vs 17 vs 0), leucopenia (48 vs 6 vs
2) and circulatory failure (48 vs 5 vs 2). CONCLUSIONS: Intra-
venous therapy with paracetamol is safer than with ketoprofen
or metamizole, concerning total number of reported adverse
events, number of reported serious adverse events and number
of hematologic disorders. Death cases were reported 15 times
more often with metamizole than with either paracetamol or
ketoprofen.
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Chronic lower back pain (CLBP) is a major economic burden on
individuals, health care system and society as a whole. Spinal
fusion surgery is recommended in patients with persistent pain.
Most lumbar spinal fusion surgery involves the use of bone auto-
graft from patient’s iliac crest, which implies increased co-mor-
bidity. InductOs® is indicated for single-level (L4–S1) anterior
lumbar spine fusion as a substitute for autogenous bone graft in
adults with degenerative disc disease (DDD). OBJECTIVE: To
evaluate the potential economic beneﬁts of InductOs® compared
to autograft, in spinal fusions in patients with DDD in Spain.
METHODS: An analytic decision tree model was developed in
order to simulate the clinical pathways of a cohort of 1000 sim-
ulated patients with DDD. The analysis was performed from the
perspective Spanish National Health System (payer), with a time
horizon of 2 years. Clinical and economical data were retrieved
from published studies and ofﬁcial tariffs, validated by a clini-
cian trained in the management of these patients in the Spanish
setting. RESULTS: In Spain, the use of InductOs® leads to a
reduction in operation times and length of stay resulting in
savings of €930 per patient, to a reduction of revisional spinal
procedures resulting in further savings of €428 per patient, and
to a faster return to work by an average of 54 days, resulting in
additional savings of €2304 per patient from sickness-leave pay-
ments avoided. These savings offset the upfront cost of Induc-
tOs® of 2799 resulting in net cost savings of €863 per case
treated, as compared to standard care. CONCLUSION: Adding
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InductOs® to the standard care in CLBP is a cost saving strat-
egy in the Spanish setting.
STROKE
PST1
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OBJECTIVES: Intracerebral hemorrhage (ICH) is among the
most costly and debilitating forms of stroke. Results from a
recent Phase IIb clinical trial demonstrate that administration of
recombinant activated factor VII (rFVIIa) reduces ICH mortal-
ity and improves functional outcome. The objective is to examine
the health plan budget impact of introducing rFVIIa as a novel
treatment for ICH. METHODS: A decision-analytic model was
adapted to estimate the budget impact of introducing rFVIIa (40,
80, or 160 μg per kilogram) for treatment of ICH, from a US
managed care perspective. The patient population was similar to
that of the Phase IIb clinical trial. Model structure and inputs
were obtained from published literature, clinical trial data,
managed care claims databases, and expert opinion. All costs are
presented in 2005 US dollars. Costs and outcomes were dis-
counted at 3 percent annually. Univariate sensitivity analyses
were conducted to assess model robustness. RESULTS: Assum-
ing a health plan of 1,000,000 members and an initial 30%
uptake of rFVIIa, the annual health plan cost is expected to
increase by between $38,868 and $279,057, or between $0.003
and $0.023 per-member per-month, depending on dose of rFVIIa
used. Assuming use of rFVIIa 80 μg/kg dose and an absolute 5%
increase in uptake each year (i.e., 55% patients receiving rFVIIa
80 μg/kg 5 years post introduction), the change in a health plan’s
annual cost is expected to be −$65,778 (cost savings) compared
to the current year’s budget at 5 years after rFVIIa introduc-
tion. CONCLUSIONS: Treating eligible patients with rFVIIa
improves survival and functional outcome. Impact to a health
plan’s budget is modest in the ﬁrst year after introduction to
market. In addition, due to expected improvements in health out-
comes, a decrease in budget impact may be observed using
rFVIIa 80 μg/kg as early as 3 years post introduction.
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OBJECTIVES: To evaluate the relation between post-stroke
physical disability and place of residence (home vs long-term 
care facility), and, secondarily, between disability and other 
economic, quality of life and caregiver burden outcomes.
METHODS: Randomly selected Erlangen Registry ischemic
stroke patients, 18 years of age or older, still alive at least 90
days post stroke and willing to attend a study visit were admin-
istered a 30-day retrospective resource use questionnaire, the
EQ-5D, the Stroke Impact Scale (SIS-16), Modiﬁed Rankin Scale
(mRS), and Barthel Index; caregivers reported resource use and
hours of informal care. Stroke history was obtained from 
registry records. Multivariate logistic and linear regressions 
were used to examine the associations. Preliminary results are
reported for the ﬁrst 200 of the planned 360 subjects. RESULTS:
At a mean time post stroke of 4 years (min 0.26—max 11.88
years), 14.5%, 25%, 25%, 13%, 7.5%, and 15% of subjects
(49.5% male; mean age 74.3 years) had mRS scores of 0, 1, 2,
3, 4 and 5, respectively. At the study visit, 72% of patients were
residing at home, and 28% were residing in a long-term care
facility. The probability of residing in long-term care was signif-
icantly higher in patients with severe disability (mRS = 3,4,5) vs
mild/moderate disability (mRS = 0,1,2) (adjusted for age, sex,
and time since index stroke; OR = 14.8, p < 0.0001). Over the
previous 7 days, 96% of caregivers of severely disabled subjects
cared for at home vs 50% of caregivers of the mildly/moderately
disabled patients at home reported ≥1 hour of informal care 
(p < 0.001); mean informal care time received by patients with
severe disability was 26.6 hours; patients with mild/moderate
disability received 6.6 hours (p < 0.001). CONCLUSIONS:
Results suggest post-stroke impairment remains an important
determinant of place of residence and caregiver burden well
beyond the acute care period, outcomes which translate into sig-
niﬁcant additional costs.
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OBJECTIVE: To estimate resource utilization and economic
costs of a stroke in Specialty Hospital (SH) of XXI Century
National Medical Center (CMNSXXI, in Spanish). METHODS:
Data from stroke-diagnosed patients who received medical assis-
tance in SH between 2003–05 were retrospectively collected,
with the following inclusion criteria: 1) assistance with <24
hours after ﬁrst symptoms, 2) CAT or magnetic resonance-con-
ﬁrmed stroke, and 3) >45 years old. The Barthel index was used
to assess clinical status. Costs were estimated from the hospital
perspective using a bottom-up approach, and only direct medical
costs were estimated (hospitalization, treatment, laboratory
tests, specialist visit, surgery). Clinical data and resource utiliza-
tion were obtained from individual clinical. The unitary costs
used are those ofﬁcially published by Mexican Social Security
institute (IMSS). A 3% discount rate was used, and prices were
adjusted as to February 2006. Results are shown either as mean-
standard (SD) or median-range and multivariate analysis test
were applied. Sensitivity analyses included variation of the
resource use frequency assumptions, percent complicated
patients and cost inputs. RESULTS: 88 patients were included,
Male 63.64%, age 55.59 (18.68), Mortality were 19.32%. More
resources were utilized for complicated patients compared to
non-complicated in CAT (1.68 vrs 1.12, p = 0.006), thorax Rx
(3.19 vrs 1.44, p = 0.002), angiography (0.41 vrs 0.19, p = 0.04)
and days of hospitalization (15 vrs 8.4, p = 0.0019). Total stroke
costs were MXN$103,493 ($101,783.2),median = $66,789.15,
range $20,158–$501,685.2). 62.36% of total costs were due to
hospitalization. Per-patient costs for a complicated and non-
complicated stroke were $151,308 and $69,926.03, respectively
(p < 0.0015). Sensitivity analysis highlighted the modelxs sensi-
tivity to the percent complicated patients and cost inputs. CON-
